Examples Of Risk Sharing Agreements

While RSAs play an important role in collecting real-world data, better patient tracking and tracking technology may be needed to effectively use risk sharing in a performance-based model. However, restrictions on digital tracking systems are becoming less and less problematic in some countries and for manufacturers as they increase their monitoring records and implement new and improved monitoring systems to meet modern health needs [71]. Is your medication better suited to a financial risk agreement or results-based? Risk-sharing contracts are tailored to specific health contexts (hospital, regional, national) as well as medical technologies and specialties. Nevertheless, there are therapies for which the application of these treaties is not simple or even necessary. In the case of low-budgetary interventions (low price and low target population), the administrative costs of these contracts are likely to be higher than the savings achieved and may therefore not be reasonable. Although monitoring health outcomes is expensive (for example. B due to a broad target audience), risk-sharing agreements based on benefit payments may not be appropriate [1, 7]. Morel T, Arickx F, Befrits G, Siviero P, van der Meijden C, Xoxi E, et al. Compatibility of cost and outcome insecurity with the need for access to orphan medicines: a comparative study on entry agreements managed in seven European countries. Orphanet J Rare Dis. 2013;8:198.

doi:10.1186/1750-1172-8-198. Risk sharing occurs when two parties identify a risk and agree to share the loss in the event of a loss due to the risk. This is usually done in joint ventures (where shareholders share the risk of loss relative to their holdings in the company), new businesses and relationships in which each party shares effective operational control. Risks can be divided pro-rata, pro-rata, sequential layers or combinations of these pie-slicing methods. Zaric GS, Xie B. The impact of two pharmaceutical risk-sharing agreements on princig, promotion and net health benefits. Health value. 2009;12 (5):838-45.

McKee S. NICE supports a shared risk system for Velcade. PharmaTimes [Internet]. 2007 June 4, 2007 Available at www.pharmatimes.com/news/nice_endorses_shared-risk_scheme_for_velcade_990036. Lucas F, Easley C, Jackson G. The usefulness and challenges of patient health systems (risk sharing) in the UK. Health value. 2009;12 (7):A243. Respondents, whose hospitals had payment or efficiency agreements (whether they also signed volume-price agreements), estimated that the number of parcels (94.1%), the size of the target group (60.0%) and drug units per year (94.1%) the main variables to take into account when signing price and volume agreements. With respect to the payment agreement for efficacy, Responder perceived that the “first class” drug (56.5%), efficacy (53.1%) uncertainty (46.9%) treatments, side effects and toxicity (53.1%) and relative safety compared to existing treatment (50.0%) were the main variables for efficiency payment agreements. For payment agreements for processing efficiency (59.2%), incremental security (42.8%) and side effects and toxicity (37.5%) were considered to be the most important variables. Trends in peer review articles on the risk-sharing agreement are represented in the number of items (blue diamond), quality (square orange) and quantitative (grey triangle).

The critical events for the price negotiations in Europe are in grey boxes and the corresponding years are marked by orange arrows. The four global themes and the corresponding calendar are represented under the x axis in blue boxes.

Write a Comment